Therapy Trends KOL Insight: Spinal Muscular Atrophy 
Despite its price, KOLs see Novartis' Zolgensma as a 'game changer' in infant SMA but will safety concerns around the intrathecal formulation slow its expansion in older populations? And as Roche/PTC Therapeutics' Evrysdi impacts the market, what role do KOLs see for Biogen/Ionis Pharmaceuticals' established market leader Spinraza? US and European KOLs critically assess the prospects of launched and pipeline therapies.
|Therapy Trends reports give you an edge by delivering actionable intelligence to help you make informed decisions about your product. Based entirely on in-depth interviews with the world's foremost KOLs, Therapy Trends research focuses on the major battlegrounds for market share and answers critical business questions about product positioning and competitiveness.|
Key questions answered
- Do experts see a future for Novartis' pipeline SMA oral therapy branaplam?
- Why do KOLs see the results of SPR1NT, STR1VE and START studies for Zolgensma as impressive?
- What's the case for continuing treatment with Spinraza after Zolgensma and will payers be prepared to meet the bill?
- How do KOLs assess the prospects for add-on pipeline SMA therapies such as Scholar Rock's SRK-015, Astellas/Cytokinetics' reldesemtiv and BioMarin/Catalyst Pharmaceuticals' amifampridine?
Examples of Therapies Covered
Partial List of Participating KOLs
|We engage the world's leading key opinion leaders, ensuring the viewpoints delivered are authoritative and consequential. Strict screening criteria ensures high-quality interviews.|
|Our-in house senior analysts and medics leverage their disease area knowledge and market research expertise to identify the key questions and issues.|
|Our reports provide a detailed analysis, based on the candid views of world-renowned KOLs, of how treatment algorithms are likely to evolve over the next 3-5 years.|
Our analysts continually monitor the market and re-engage KOLs throughout the year, delivering event-driven KOL insights on the impact of market changing events such as new clinical trials, pivotal trial results, drug approvals, drug launches and safety alerts.
Short on time? All reports are supported by a convenient slide pack summarising the core of the analysis, making it easy to share with key stakeholders.
Our reports cover the pipeline products that will shape the future, helping you uncover where threats and opportunites will emerge.
Extensive KOL interviews result in hundreds of direct KOL quotes, providing you with an unbiased and comprehensive view of key market-shaping issues.